Phase 2/3 study comparing Masitinib/Placebo in ALS V1.1

• Research type

  Research Study

• Full title

  A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 Study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).

• IRAS ID

  142949

• Contact name

  Aleksandar Radunovic

• Contact email

  aleksandar.radunovic@bartshealth.nhs.uk

• Sponsor organisation

  AB Science

• Eudract number

  2010-024423-24

• REC name

  London - Bloomsbury Research Ethics Committee

• REC reference

  14/LO/0337

• Date of REC Opinion

  28 Mar 2014

• REC opinion

  Further Information Favourable Opinion